MaxCyte,
Inc.
("MaxCyte" or the "Company")
Total Voting Rights and Block
Listing Return
ROCKVILLE, MD, April 3,
2024: MaxCyte,
Inc., (Nasdaq: MXCT; LSE:
MXCT), a leading, cell-engineering focused
company providing enabling platform technologies to advance the
discovery, development and commercialization of next-generation
cell-based therapeutics and innovative bioprocessing
applications,
announces that pursuant to its block
admission facility, since 29 February 2024 it has
issued 298,824 of common stock, $0.01 par, of the Company
("Common Stock") in satisfaction of the exercise of share options
and/or vesting of restricted stock units.
Total voting rights
As at 31 March 2024, the total
issued stock capital of the Company following the recent issue of
the new Common Stock is 104,395,574 shares of Common Stock.
Shareholders in the Company may use this figure as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the stock capital of the Company.
Block Listing
Return
MaxCyte also makes the following
notification pursuant to AIM Rule 29 and Schedule Six of the AIM
Rules for Companies, regarding its existing block
listings:
|
Name of applicant:
|
MaxCyte, Inc.
|
|
Name of scheme:
|
MaxCyte Long Term Incentive
Plan
|
|
Period of return:
|
From:
|
1 August 2023
|
To:
|
31 March 2024
|
|
Balance of unallotted securities
under scheme(s) from previous return:
|
9,929,345 ordinary shares of common
stock at $0.01
each
|
|
Plus: The amount by which
the block scheme(s) has been increased since the date of the last
return (if any increase has been applied for):
|
Nil
|
|
Less: Number
of securities issued/allotted under
scheme(s) during period (see LR3.5.7G):
|
891,003 ordinary shares of common
stock at $0.01
each
|
|
Equals: Balance under
scheme(s) not yet issued/allotted at end of period:
|
9,038,342 ordinary shares of common
stock at $0.01
each
|
|
|
|
|
|
|
|
Name of contact:
|
Douglas Swirsky, Chief Financial
Officer
|
|
Telephone number of
contact:
|
+1 301 944 1700
|
For further information, please
contact:
|
|
MaxCyte Contacts:
US IR
Adviser
Gilmartin Group
David Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure Gordon
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
|
|
UK IR
Adviser
ICR
Consilium
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
|
|
|
|
|
|
|
|
|
|
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been designed to support
the rapidly expanding cell therapy market and can be utilized
across the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at
maxcyte.com and
follow us on X (formerly Twitter) and
LinkedIn.